Chat with us, powered by LiveChat

Webinars

Modeling Gut-Liver Interaction Using EpiIntestinal™ Micro-Tissues In the Human Dynamic Multi-Organ Plate (HuDMOP™).

Panelists 

Seyoum Ayehunie, Ph.D.

Jamin Willoughby, Sr., Ph.D.

On May 2nd you are invited to join MatTek Corporation and IONTOX, LLC for a joint webinar on the MatTek EpiIntestinal™ model and a new and unique way in which this model is being used to study cholestatic drug-induced liver injury in vitro, using the patented Human Dynamic Multi-Organ Plate 

[dt_button link=”https://www.youtube.com/watch?v=e6en64MimNQ” size=”big” color_mode=”custom” color=”#dd3333″]Watch The Recording [/dt_button]

A New In Vitro Method to Predict the IDILI Potential of Drug Candidates

Panelist

Robert A. Roth, Ph.D., DABT

 

Preclinical safety testing does not always predict drug toxicity in human patients. There are many examples of drug candidates that were found to have acceptable preclinical safety testing and clinical trial profiles and were approved for marketing only to be withdrawn or have their use restricted after causing idiosyncratic drug-induced liver injury (IDILI) in patients.

Our growing knowledge of events underlying IDILI pathogenesis has led to an improved understanding of preclinical prediction of IDILI liability of drug candidates. In this webinar, we will be discussing a new in vitro assay that holds promise for predicting IDILI.

 

[dt_button link=”https://attendee.gotowebinar.com/register/7791062816625799682″ size=”big” color_mode=”custom” color=”#dd3333″]Watch The Recording [/dt_button]
The Use of a Multiple Organ Plate Model for Evaluating Pharmacokinetics and Toxicity of Drugs and Chemicals In Vitro.

 

Panelist

James McKim, Ph.D., DABT

A webinar discussing an innovative new platform that enables investigators to evaluate drug or chemical pharmacokinetics/pharmacodynamics and toxicity in an in vitro multiple organ model.

[dt_button link=”https://attendee.gotowebinar.com/recording/1386350409428273933″ size=”big” color_mode=”custom” color=”#dd3333″]Watch The Recording [/dt_button]
The C-DILI™ Assay. Predict cholestatic liver injury.

Panelists

Kenneth R. Brouwer, Ph.D., RPh.

James McKim, Ph.D., DABT

The C-DILI™ Assay. Predict cholestatic liver injury. The C-DILI™ Assay is a novel in vitro method to evaluate a compound’s potential for cholestatic drug-induced liver injury (DILI).

[dt_button link=”https://www.youtube.com/watch?v=BQZ1GIskzik” size=”big” color_mode=”custom” color=”#dd3333″]Watch The Recording [/dt_button]